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study
Erika A Waters1,4*, Linda Ball1, Kimberly Carter2 and Sarah Gehlert1,3

Abstract
Background: Several genetic variations associated with nicotine dependence and lung cancer exist. Translating this
knowledge into tobacco control policy relies on smokers’ perceptions of the implications of the research. This study
explored smokers’ beliefs about the tobacco control uses for research examining genomics, smoking, and addiction.
Method: Smokers (N = 85) participated in one of thirteen focus groups and one interview, stratified by race (eight
black, six white) and education (seven < Bachelor’s degree, seven ≥ Bachelor’s degree). Data were analyzed by two
independent coders using standard analysis and validation techniques.
Results: Nearly all groups suggested using genetic information for youth-oriented tobacco prevention education.
Beliefs about the effectiveness of such actions varied. Many participants believed that providing smokers personalized
genetic testing results or informing them about the existence of a gene would not motivate people to quit. All smokers
emphasized the need for improved smoking cessation treatment options. Using genomics research to develop gene
therapies and personalized drug treatments were also mentioned, yet perceptions of such treatments were mixed.
Whereas some participants viewed the possibility positively, others expressed concern about cost and access.
Participants who were skeptical of the effectiveness of using genetic information for tobacco control noted that
the harms of tobacco use are widely known and genetic information does not add much of a deterrent.
Conclusion: Participants generated several possible tobacco control uses for genomics research findings. Our
findings suggest that tobacco control experts should consult with smokers prior to implementing tobacco control
measures. The potential public health benefits of genetics and genomics research related to tobacco use cannot be
realized until communication strategies that are most likely to encourage and support tobacco avoidance decisions,
and minimize mistrust and backlash, are identified.
Keywords: Gene-environment interaction, Smoking cessation, Tobacco prevention, Health promotion, Personalized
medicine, Tobacco control

Background
Extensive research has examined the association of genetic
variants with a variety of tobacco use outcomes, including
susceptibility to nicotine addiction, smoking-related diseases, and responsiveness to pharmacological smoking
cessation aides [1,2]. The goal of many of the studies is
to use research findings to develop biomedical and
* Correspondence: waterse@wudosis.wustl.edu
1
Department of Surgery-Division of Public Health Sciences, Washington
University in St. Louis, Saint Louis, MO, USA
4
Division of Public Health Sciences, Washington University School of Medicine,
Campus Box 8100, 660 S. Euclid Ave, Saint Louis, MO 63110, USA
Full list of author information is available at the end of the article

behavioral interventions that reduce tobacco morbidity
and mortality.
The potential utility of using personal genetic testing
to motivate smoking cessation has been debated for
several years [3-5]. Early debates have been supplemented
by a growing body of research, including meta-analyses
and systematic reviews, that suggest that providing
smokers with personalized test results for high-risk
genetic variants may have limited effectiveness in encouraging cessation [6-8].
Tailoring smoking cessation therapies according to
genotype rather than providing general information
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about smoking risks may be a viable alternative; smokers
and physicians report interest in using genetic testing
for this purpose, despite several remaining barriers (e.g.,
perceived unimportance of medications among some
smokers, physicians’ concerns about the ability to counsel
patients effectively) [9,10]. However, research examining
the efficacy of tailoring smoking cessation therapies by
genotype is nascent. To date there is only one published
randomized controlled trial that examined the effects of
tailoring nicotine replacement therapy (NRT) dose by
genotype [11]. It reported that tailoring NRT dose by
genotype resulted in higher 6-month abstinence than
tailoring dose by phenotype. A follow-up study reported
that participants who received more intensive NRT were
more successful quitting, but it did not indicate whether
NRT dosage or duration mediated the effect of genetic
tailoring on cessation [12]. The paucity of data means that
several years will pass before adequate efficacy data are
published and tailored smoking cessation interventions
are widely used. Thus, alternative uses for tobacco-related
genomic research should be identified.
Another complication is that people with limited
access to healthcare almost certainly will have limited
access to genomics technologies. This raises the possibility
that translating genomic technologies from bench to
bedside might inadvertently worsen existing cancer disparities [13] by virtue of being unavailable to underserved
populations. For example, if smokers cannot afford the
genotyping needed for individualized cessation therapies,
they may be less likely to quit and therefore at increased
risk of morbidity and mortality. Thus, the only exposure
to genomic information for smokers with limited access
to healthcare may be via media outlets and social networks [14].
This paper explores smokers’ beliefs about the potential
for genomics research to inform effective tobacco control
policies and programs. We solicited smokers’ ideas because
the translation of research from basic genomics to policy
implementation requires the involvement of key stakeholders [15,16]. Lack of involvement can impair an intervention’s effectiveness by ignoring critical factors that
might otherwise impede implementation. The data presented are a subset of data collected for a study aimed
at understanding smokers’ opinions about the discovery
of a genetic variation associated with increased risk of
severe nicotine addiction and lung cancer [1]. We
examined possible differences in beliefs according to
race and educational attainment because these variables
are strongly related to smoking prevalence and cessation
success [17]. This study focused on understanding the
dissemination of genomics research findings via mass
media rather than through clinics based on the premise
that access to clinical genetic testing will likely be limited
for many individuals.
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Methods
Study description

This qualitative study used focus groups to explore participants’ perspectives and beliefs about the link between
genetics and nicotine addiction. We chose to use focus
groups because we believed that their dynamic and interactive nature would produce higher quality and more
complete data than would interviews, due to the relatively
low levels of knowledge about genetics in the general
population [18]. This is because focus group members
tend to stimulate each other’s thinking about topics about
which they normally do not converse [19].
Focus groups were stratified by race (African American,
White) and educational attainment (<Bachelor’s degree, ≥
Bachelor’s degree), resulting in four strata: higher education/African American (HA), lower education/African
American (LA), higher education White (HW), and lower
education White (LW). This reflects previous findings in
which African American and White participants reported
different concerns about the potential misuse of genomic
information [20] and reluctance to share that information
in racially diverse settings. It is also consistent with surveillance data indicating that the prevalence of tobacco use
is lower for people with at least a Bachelor’s degree [17].
Accordingly, each group was facilitated by a moderator
and a note-taker who were race-matched to the group.
Ethical approval and consent

The study team obtained approval to conduct the research
from the Washington University School of Medicine
Human Research Protection Office and the Siteman
Cancer Center Protocol Review Management Committee
prior to initiating recruitment. All participants provided
signed informed consent upon arrival at the focus group
interview site.
Participants and procedure

Eligibility criteria were: at least 18 years old, having smoked
at least 100 cigarettes, currently smoking every or some
days of the week, self-identifying as African American or
White, not considering oneself to be an expert in genetics,
having watched, listened to, or read the news at least once
in the past week, being able to demonstrate rudimentary
knowledge of the terms “gene” or “genetic”, and being able
to speak and read English.
Participants were recruited via flyers distributed in
public venues such as community events, and small local
businesses such as retail stores, music stores, tattoo parlors,
tobacco shops, corner markets, restaurants, and laundromats. Recruitment also occurred via snowball sampling
(i.e., word of mouth) and using a registry of research
participant volunteers. Participants were screened and
scheduled by telephone. Upon arrival at the focus group
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location, participants were consented and completed a
brief survey re-assessing demographic and tobacco history
information.
The focus group began with brief introductions and
warm-up questions about reasons for smoking and the
meaning of “genes” and “genetics”. Terms were then
explained briefly to ensure a minimal level of common
understanding. Participants shared their thoughts about
possible links between genes, diseases, and smoking, and
then viewed an Associated Press video clip that described
the discovery of a genetic variant associated with nicotine
addiction and lung cancer [1]. The video was one minute
long and can be viewed at http://youtu.be/sO3X8xBr8YQ.
It indicated that three separate scientific teams discovered
a genetic variant that conferred an increased risk of severe
nicotine addiction and an 80% increased risk of lung cancer. The video also indicated in a very general way that
the results give hope for improved smoking cessation
treatments. Images of cigarettes, smokers, and technicians
pipetting samples were included in the video.

The moderators used a semi-structured interview guide
that included broad open-ended questions intended to
elicit beliefs about the link between the variant and
nicotine addiction and lung cancer (Table 1). Targeted
open-ended probes were crafted to assess beliefs about
the potential uses of the information and other topics of
interest if the topic was not mentioned by any group member spontaneously. Questions and probes were phrased
in non-academic, informal language, and approached
the target construct indirectly to reduce the risk of biasing
responses by asking leading questions [19]. Groups lasted
approximately 90 minutes and were audiorecorded. Participants received a $40 gift card and a light meal.
Data analysis

Audiorecordings were transcribed and examined for
accuracy. Data were analyzed using domain analysis [21].
Themes and subthemes were identified deductively, based
on the study’s a priori areas of interest, and inductively
to identify concepts that emerged spontaneously from

Table 1 Example questions and probes used in focus groups
Pre-video questions and probes
1.

There are lots of reasons why people smoke cigarettes. What is your MAIN reason for smoking?

2.

What comes to mind when you hear the words “genes” or “genetics”?

3.

Sometimes you hear people talking about a genetic risk for a disease. What do you think “genetic risk” means?
What does it mean for a person to have “genetic risk”?

• PROBE: “What have you heard about nicotine in relation to cigarettes”

• PROBE: If I had a genetic risk for cancer, does that mean I’d definitely get it?
• PROBE: What might make one person with a genetic risk more likely to get sick than another person with a genetic risk?
• PROBE: Thinking about the term “genetic risk,” in your opinion, what does it have to do with smoking?
Post-video questions and probes
4.

What do you think of the video?
• PROBE: Was there something that really made an impression?
• PROBE: What types of feelings came up as you were watching the clip?

5.

When some people hear that genetics and nicotine addiction are related, they do not believe this is true. On the other
hand, there are other folks who do believe that genetics and nicotine addiction are linked. What do you believe?
• PROBE: How important or relevant is this information for you personally?
• PROBE: How do the concepts presented in the video relate to your personal experiences?

6.

If a smoker has this gene, will they definitely not be able to quit?
• PROBE: What role does willpower have in quitting smoking when someone has a gene for nicotine addiction?
• PROBE: If you knew you had the gene, would you still try to quit?

7.

What could be some of the benefits of people knowing that there’s a genetic basis for nicotine addiction?
• PROBE: Could you see this information being used to help motivate someone to quit?
• PROBE: What about being used to discourage people from starting to smoke?

8

What could be some disadvantages, or drawbacks of knowing about this information?
• PROBE: Would YOU want to know whether or not you have the gene?
• PROBE: How might this information change people’s opinions of smokers?
• PROBE: How much should people be concerned about discrimination as the result of this news story and stories like it?

Note: Probes only asked if the answers to the main questions did not address topic of interest.
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participants. Two authors (EW, LB) separately listened to
and read the transcripts and identified potential themes.
Using an iterative process, these themes were discussed
and a preliminary codebook was developed. The preliminary codebook was reviewed by SG and feedback was
provided. After coding and discussing one transcript
from each of the four strata, the codebook was finalized
after additional consultation with SG. The remaining
transcripts were coded, with the coders conferring regularly to discuss discrepancies. After coding was completed,
broad patterns of findings and major themes were identified with special attention given to areas of saturation.
NVivo was used for analysis. SG was consulted to provide
feedback during each phase of the analysis process and to
resolve challenging coding discrepancies.

Results
Participant characteristics

We conducted 13 focus groups and one interview that
included 85 total participants (see Table 2). There were
four groups for each of the HA and LA strata, three
Table 2 Participant characteristics (N = 85)
Mean

SD

42.8

12.9

n

%

Men

44

51.8

Women

41

48.2

African American

52

61.2

White

33

38.8

Age

Sex

Race

Education
<High school
High school/GED

6

7.0

17

20.0

Vo-Tech

5

5.9

Some college

29

34.1

Bachelor’s degree

19

22.4

Postgraduate degree

9

10.6

Daily

78

91.8

Some days

7

8.2

5

5.9

1-9

28

32.9

10-19

27

31.8

20-29

20

23.5

30-39

3

3.5

40+

2

2.4

Smoking frequency

Number of cigarettes smoked daily
<1

groups for the LW strata, and two groups and one interview for the HW strata. Focus group size averaged six
participants with a range from three to ten. Due to an error
in data collection, the data from the interview (n = 1) was
unusable. The findings below are based on the focus group
data only (n = 84).
Themes

There was no consensus among participants about whether
the video presented true information about the relationship between genetics and nicotine addiction and lung
cancer (forthcoming manuscript). In every group, at least
one participant—and sometimes several participants—made
a statement suggesting that he or she was skeptical of the
validity of the information. In two of the African American
groups, at least one participant had such strong doubts
that they had difficulty answering questions about the
potential benefits and drawbacks of providing genetic
risk information to smokers. Participants were permitted
several minutes to discuss their reasons for disbelieving
the information. Then, for the purpose of generating
conversation and moving the focus groups forward,
participants were asked to suspend their disbelief and
imagine that the information was true.
Six themes emerged that addressed how research about
the smoking-genetics link might be utilized for tobacco
control purposes. The themes are described in detail in
each of the five subsections below. Importantly, no racial
or educational differences emerged about any of the tobacco control themes described below.
Improved but potentially costly therapies

Eight of the thirteen (62%) groups mentioned that the
discovery of a genetic basis for nicotine addiction and
lung cancer might lead to the development of novel
treatments or preventive agents. One possibility was to
use genetic information to identify the optimal pharmaceutical therapy for a given patient:
[HW] Man 1: “…if they [the researchers] knew more
about where that’s [nicotine] affecting their brain,
they [the researchers] can…pinpoint [a] more effective
drug or treatment perhaps…you can say, ‘Well, we
have this drug now to target those people with
this gene…’”
Participants also mentioned gene therapy and genetic
manipulation:
[LW] Man 2: “…there’s a ton of things that…could be
started to prevent…a child from getting [addicted]…
even just eliminating it altogether to where
something, you know, erases that particular part
of genealogy…”
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However, the possible cost of such treatments was a
concern:
[LA] Woman 1: “…Do you all know if we can alter
the gene? Is there something we could do to change it
maybe?
Woman 2 responds: “You got to pay for everything.”
As these quotes demonstrate, participants saw the
potential for genomics research findings to be used in
complex ways to treat or prevent nicotine addiction in
adults and children. Yet, statements made by some participants suggest that the cost of such treatments may
prohibit access for people without sufficient means.

Page 5 of 9

got this stuff here. If you drink that, then your
chances get 20% better’…then I might consider doing
somethin’ with that information.”
These quotes illustrate the complex and multilevel nature
of the process by which the provision of personalized
genomic testing may or may not influence cessation.
The extent to which the information is motivating is
highly dependent on the individual. However, the sheer
difficulty of quitting raises concerns even in motivated
smokers about whether they will be able to transform
their intentions into successful actions. Nevertheless,
many participants indicated that they would more open
to testing if effective treatments were available.
Smoking prevention in youth

Personalized genetic testing

The potential of personalized genetic testing for smokers
arose in all 13 (100%) groups. Participants identified
several avenues by which providing genetic test results
may or may not affect behavior. However, opinions differed about the extent to which providing test results
would motivate people to quit smoking.
[LA] Woman 2: “It would make a difference to me
seriously…If I went to the doctor and they said, oh,
you got the “double-whammy gene” [quoted from
video] for smoking…I’ll be like oh really, I’m going to
try harder to quit smoking.”
[HA] Woman 1, in response to moderator question
about quitting after genetic testing: “I don’t think so.
It has to take something to happen for you to want
to…quit.”
In contrast, one participant saw the potential utility of
personal genetic testing for motivating smoking cessation, but he was less confident in his ability to put the
information into action:
[HW] Man 4: “If I got screened tomorrow and
they told me that I had this, I don’t know. I can’t
say….I had the threat of losing this tooth, and was
able to quit…but once I was healthy, went right
back to it.”
Other participants emphasized the idea that providing
personalized test results to long-established smokers
would be useless unless therapies were available to help
them quit:
[LW] Woman 5: “If you come to me tellin’ me this
[points to paper summary of video]…I will roll my
cigarette in that paper. But if you tell me, ‘Hey, but we

The potential to use the information to discourage children
and adolescents from beginning to smoke was mentioned
in 12 of the 13 (92%) groups. However, like personal genetic testing, participants held widely divergent views about
its effectiveness:
[LA] Woman 4: “I think [knowing about the gene will
make it] harder to start [smoking] because you’re
going to get lung cancer.” …
Man 2 responds: “I expect the kids…might get it [be
positively affected by the information] before the
grownups will.”
Whereas some participants believed that providing
young people with their personal genetic test results might
be an effective deterrent to smoking, others disagreed by
highlighting existing public health messaging surrounding
tobacco use:
[HA] Man 3: “They test you early on…and you
know that you have it, so that you have a—that
with this gene comes a certain death percentage
already if you start smoking…they can basically
put it in your hands whether you want to start
smoking or not.”
Man 1 responds: “We had, ‘it’ll stunt your growth, it’ll
give you lung cancer’ and all… it didn’t stop us then.
So what’s the difference?”
The possibility that providing information to young
people might backfire and increase their susceptibility to
experimenting with smoking also arose:
[LW] Man 2: “…I’m not really skeptical, but… what’s
the first thing a kid does when you tell him not to do
something?”
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Some participants were relatively optimistic about the
potential of genetic testing to prevent tobacco use in
young people, especially in comparison to adults, but
others disagreed. Those who were optimistic discussed
the idea of young people being able to choose to smoke
or not based on having as much information as possible,
but others indicated that knowledge did not motivate
their smoking behavior. There were also concerns about
the information potentially backfiring.
Mass media communication

Using the mass media to motivate smokers to quit by
disseminating the study findings arose in only four (31%)
groups, and then only in response to the moderator’s
direct inquiry. Opinions tended to be highly negative:
[LA] Moderator: “If that were on TV right now…”
Man 2 responds: “I think it would be a waste of
advertisement.”
[HA] Moderator: “What would the reaction be of…
folks if they see this?”
Man 2 responds: I see them turning the TV off.
<laughs>
In contrast to these definitive rejections of the information, a few participants believed that responses to
mass media-based information would depend on individual situations:
[LW] Woman 3: “I think yes and no… some people
will be like, ‘Screw it, I’ve been smokin’ for 42 years,
what’s the point?’ And… some people will be like, ‘You
know what, my first cigarette was just like a year and
a half ago. Let’s do this.’ You know?”
Participants indicated that there would be considerable
rejection of mass media-based educational campaigns centered on the study’s findings. This rejection was thought
to take both overt actions such as turning the television
off, and more cognitively-based rejection. Potential acceptance of the information was voiced infrequently.
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[HA] Woman 3: “And it’s not that we don’t know what
the consequences of smoking are. You know…when I
was in high school…they showed us this movie about
smoking, and how your lungs look, and all that…You
just say, ‘Okay, I saw that, and…intellectually, I
understand.’ But I would choose to smoke.”
Some participants believed that knowledge about the
hazardous effects of tobacco was universal, in part due
to mass media campaigns. Thus, informing people about
the genetic link to nicotine addiction and lung cancer
would be superfluous:
[LA] Woman 2: It ain’t going to help nothing because it’s
already a known fact that these bad boys are disgusting.
It’s not going to help because it’s all over the whole
world. Do not smoke…you’re gonna be toe-up [dead].
And they even have commercials and everything.”
Other participants placed their existing knowledge of
the hazardous effects in the context of others confronting
them about their smoking behavior. This was distressing.
[HW] Woman 1: “Oh my gosh! My daughter came
home with [tobacco education material]. That’s a
killer, you know?”
Woman 3 responds: “Because we know…We’re gonna
die, because we’re smoking. So you don’t have to put
it in our face. And the stupid young kids that start
smoking, they’re not sitting down watching this stuff.”
[angry tone of voice]
The vast majority of participants were well aware that
smoking is harmful to health. This awareness came from
various sources, including school-based prevention efforts
and mass media campaigns that included elements that
were highly graphic and generated disgust. Participants
were also confronted about the hazards of smoking by
loved ones. In that context, relatively emotionally pallid
information about a genetic basis for nicotine addiction
and lung cancer was insufficiently motivating. Nevertheless,
some participants voiced frustration at smoking initiation
among young people.
Personal agency and motivation

“We know” smoking is hazardous

Those participants who were skeptical about using genetic information to discourage smoking emphasized that
adolescents and smokers already know that smoking is
hazardous, yet that knowledge does not affect behavior.
These points were raised in ten (77%) of the groups.
Some comments focused on school-based tobacco prevention efforts:

Although opinions diverged widely about the utility of
information about the genetic basis for nicotine addiction,
the data suggested that, for many participants, the motivational quality of the information was associated with
participants’ beliefs about the importance of smoking and
smoking cessation as conscious choices. It should be noted
that the specific question of the extent to which genetic
risk information might be motivating was contingent
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on participants either believing the information provided
or suspending their disbelief. Participants who disbelieved
the information cited the importance of personal agency
as a reason for their disbelief (data not shown).
Like others, this participant emphasized the ability of
the information to help novice smokers decide to quit
before addiction becomes too severe:
[HW] Man 3: “If…you had that information up front
[before addiction sets in]…you can make it a clear
decision…with that information, say “Okay. I’m
not—since I’m more susceptible to that, I’m gonna
take extra effort not to be caught up in it.”
Other participants focused on the ability of the information to increase willpower when quitting:
[LA] Woman 3: “It [the information] help you say,
hey, the gene is not going to control me, I’m going to
control it…put my foot down and stomp on it.”
Participants who reported they would be less motivated
by the information made statements that were either less
focused on personal agency, or made statements that
indicated a lack of agency:
[LW] Man 2: “I didn’t really realize it was that—the 80
percent. I mean, both my parents died of cancer and I’m
probably right in the top of that number, but you know,
as far as quittin’ goes…it just doesn’t even seem like an
option…I mean, I, I tried it just doesn’t happen…and I’ve
accepted the fact that it’s not gonna happen.”
Although there was near universal agreement that
smoking initiation and cessation were conscious choices
(data not shown), the role of personal agency in the ability of genetic information to motivate quitting was more
varied. Specifically, participants who discussed the motivational value of the information in terms that included
agentic statements indicated that the information was
more motivating than participants who did not use agentic statements.

Discussion
Study participants discussed multiple uses for information
about the genetic basis for nicotine addiction and lung
cancer, despite widespread skepticism about the validity of
the research itself. These uses included encouraging
smoking cessation and discouraging smoking initiation by
providing people with their personal genetic test results,
implementing mass media or other health education campaigns, and developing novel biomedical therapeutics.
The perceived effectiveness of the tobacco control
strategies varied. Consistent with other research [22],
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biomedical therapies were seen as potentially highly
effective, yet expensive. These concerns were reasonable;
adolescent primary care providers reported less willingness to offer testing for genetic variations associated with
nicotine addiction if patients had no health insurance
[23]. In contrast, beliefs about the potential effectiveness
of genomics-based health education were mixed. Some
participants thought that providing personalized genomic
test results—or even informing people of the discovery of
the genetic variant—might encourage some smokers to
make a quit attempt and possibly discourage some young
people from starting to smoke. Others were more
skeptical, explaining that the overwhelming majority of
smokers know that smoking harms health and know that
they should quit. These findings are consistent with other
research, [24-26] although [24] did not report that participants were skeptical about the ability of the information
to motivate cessation. Participants who were more open
to the potential ability of genetic testing to motivate cessation may have had a stronger focus on personal agency
than those who were more skeptical. This is consistent
with research indicating that quitting self-efficacy is important for cessation success [27]. Nevertheless, this specific finding needs to be replicated because the relevant
focus group data were relatively sparse. Concerns about
potential discrimination as a result of testing were also
raised in a way similar to prior research (forthcoming
manuscript) [22,26,28].
Prior studies examined the feasibility and effectiveness of
using personalized genetic testing to encourage smoking
cessation [10,22,24,25]. We extend this research by examining opinions about a broader array of possible tobacco
control measures, including approaches not requiring
medical testing (i.e., mass media dissemination). However,
formal mass media campaigns may have limited effectiveness, and may not communicate this type of information
effectively [28].
Another novel finding is that skepticism about the
effectiveness of genetic-based prevention efforts may stem
from the belief that, thanks to current tobacco control
efforts, people think they already understand smoking
risks. In that context, the incremental threat of providing
genetic information is insufficient to motivate change.
However, although smokers know that smoking is “bad
for them” in a general way, they are likely unaware of the
extent to which tobacco use harms the entire body [17,29].
Emphasizing lesser-known consequences of smoking in
conjunction with genetic counseling might be beneficial.
Paying special attention to appearance-based consequences
in campaigns oriented towards younger smokers might
increase the relevance for that important subgroup [30].
One reason the information may be insufficiently motivating is because genetic information may be less emotionally
impactful than the graphic and visceral images and stories
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included in many smoking prevention and cessation campaigns, such as the Tips from Former Smokers campaign
sponsored by the U.S. Centers for Disease Control (http://
www.cdc.gov/tobacco/campaign/tips/).
Strengths, limitations, and future research

Due to a concerted targeted recruitment effort, most of our
study participants (61%) were African American and people
with less formal education (68%). This lends confidence
that our conclusions are applicable to two demographic
groups that experience disproportionate difficulty quitting
and morbidity and mortality from smoking-related illnesses
[17]. However, we also recruited whites and individuals
with more formal education to allow examination of
between-group differences that might influence the development of future interventions. Yet we failed to detect
between-group differences.
There may be concerns about the demographic and tobacco use characteristics of the study participants. Approximately 50% of people with less than a Bachelor’s degree
reported having “some college” experience. This is a higher
proportion than in the region from which participants were
recruited [31]. It is unlikely that this influenced the study
findings, however, because genetics knowledge was also
limited in groups with more formal education. We also had
exceptional difficulty recruiting smokers with at least a
Bachelor’s degree. It is possible that the lower prevalence of
smoking among highly educated people is related to stronger negative social norms about smoking, which may have
increased reluctance to acknowledge participating in a stigmatized behavior. The smokers in our study smoked an
average of 10–19 cigarettes per day. Thus, these results
may not generalize to light or intermittent smokers. Future
research should examine those vulnerable groups more
closely. Future studies might also use quantitative methods
to understand the prevalence of these beliefs in different
populations, informed by the results of qualitative studies
like ours.

Conclusions
This paper advances the effective translation of basic
genomics research into tobacco control interventions,
programs, and policies by beginning to understand the
perspectives of current cigarette smokers, a key stakeholder
group. We found that, for reasons discussed previously,
broad mass media-based dissemination associating nicotine
addiction and lung cancer with certain genetic variants is
unlikely to motivate large numbers of smokers to quit, or
to discourage young people from starting. Interpersonalbased dissemination of the information incorporated into
school-based tobacco prevention might be effective for
some students, but is likely to be met with considerable
skepticism and may backfire.
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Despite research indicating that personalized genetic
testing is ineffective in promoting cessation [6], it might
be more effective for a subset of the population. However,
this subset needs to be identified and characterized. The
effectiveness of genetic testing would likely be maximized
if testing is used to target specific biomedical therapies to
specific individuals, rather than simply informing patients
that they “have the gene.” However, populations with the
highest use of tobacco and/or the most difficulty quitting
are medically underserved [17]. Unless the genetic testing
process and accompanying therapies are inexpensive and
easily accessible to medically underserved populations,
individuals at highest risk of tobacco-related morbidity
and mortality may be those for whom beneficial therapies
are inaccessible. This raises the possibility of genetic testing inadvertently exacerbating existing tobacco-related
health disparities.
These findings also highlight the fact that genomic risk
information does not exist in a vacuum. Rather, it exists
in a living context that allows people to reject both the
information (see also [32]) and its potential uses. This
context is informed by a multitude of factors including,
but certainly not limited to, preexisting knowledge about
the topic, prior personal experiences, and attitudes about
the healthcare system, economics, human development,
and in some cases the importance of personal agency for
action. Complicating matters further is that these factors
are steeped in emotion, as suggested by the statements
illustrating the “We Know” theme. Attempting to communicate genomic risk information without attending to at
least some of these factors is unlikely to achieve widespread
success [33,34]. This may be especially true for tobacco use,
which is highly addictive and has been the subject of health
education campaigns for the last 50 years [17].
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